China's BCI Industry Accelerates Amid Neuralink Skepticism
While Elon Musk's Neuralink faces growing skepticism about its long-term profitability, China is rapidly advancing its own brain-computer interface sector. A global race is underway, with Chinese government and private investment aiming to accelerate BCI applications in clinical, industrial, and consumer use cases.
- In August 2025, several Chinese government bodies, including the Ministry of Industry and Information Technology, issued a national roadmap for BCI development, setting a goal to achieve key technological breakthroughs by 2027. This plan aims to establish a full supply chain and build globally competitive BCI companies by 2030. - To fuel this growth, China announced an 11.6 billion yuan (about $165 million) brain science industry fund in December 2025 to support companies from early-stage research through commercialization. Projections show China's BCI market growing from 3.2 billion yuan in 2024 to over 3.8 billion yuan ($534 million) in 2025. - Chinese startups are reaching clinical milestones rapidly. Shanghai-based NeuroXess, founded in 2021, has already conducted human trials enabling a paralyzed patient to control a computer cursor. Another company, StairMed Technology, completed China's first invasive BCI clinical trial in May 2025, helping a quadruple amputee regain some daily living abilities. - The country is also streamlining commercialization by integrating BCI into its national medical insurance system. In March 2025, the National Medical Insurance Administration created a new insurance category for BCI technology, a step that could significantly accelerate adoption by addressing affordability. - In contrast, skepticism around Neuralink stems from several concrete issues. The U.S. Food and Drug Administration (FDA) has raised safety concerns about the device's lithium battery, the potential for its wires to migrate within the brain, and how it can be removed without causing damage. - Chinese firms are also innovating on the core technology. Wuhan Zhonghua Brain Computer Integration Technology Development Co. claims to have developed a 65,000-channel bidirectional interface chip, far exceeding the mainstream 3,000-channel standard. Additionally, Shanghai-based Ladder Medical is developing ultra-flexible electrodes designed to reduce the risk of tissue damage and immune rejection.
